Predict your next investment

Venture Capital
biosciencemanagers.com

See what CB Insights has to offer

Investments

17

Portfolio Exits

2

Funds

3

Partners & Customers

1

About BioScience Managers

BioScience Managers, formerly IB Managers, is a life sciences investment firm, headquartered in Melbourne, Australia. Established in 2003, BioScience Managers offers a global, multi-disciplinary team, bringing an international perspective together with the track record, networks and expertise required to convert that perspective into informed, high return investment decisions. The firm operates a high value-add model, providing assistance and support to portfolio companies via our global team and international network of independent industry advisors. With combined experience of over 170 investments, more than 40 IPO's/ reversals in Europe, the USA and Australia, and a diverse skillset specific to the bio-based industries, BioScience Managers aims to provide investee companies with significant value-add over and above capital invested.

BioScience Managers Headquarter Location

Level 12 15 William Street

Melbourne, Victoria, 3000,

Australia

+61 3 9618 8248

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest BioScience Managers News

Millions in Australian taxpayers’ dollars invested in struggling NZ exoskeleton company

May 22, 2021

Advertisement An Australian government fund meant to support local biomedical development invested millions in a struggling New Zealand-founded exoskeleton company that has almost no staff in Australia. Rex Bionics, which manufactures $150,000-plus exoskeletons for wheelchair users, employs only one person in Australia , and is running no local clinical trials. Research, development and manufacturing all remain based in New Zealand. Minister for Health Greg Hunt with Australian Institute of Neuro-rehabilitation director and spinal injury victim Louis Rowe demonstrating the Rex Bionics Exoskeleton. Credit:Twitter The roughly $6 million taxpayer investment was guided by an international investment firm, BioScience Managers. BioScience Managers was appointed in 2016 as a manager of the Turnbull government’s flagship Biomedical Translation Fund, which had $250 million in taxpayer and $250 million in private funding to invest. The idea was to have BioScience Managers make “commercially defensible” investment decisions with taxpayer money, a government spokeswoman said. In 2017, Health Minister Greg Hunt stood with a patient wearing Rex’s exoskeleton at a news conference in Canberra. He lauded Australia’s investment in Rex and and two other companies as supporting “high potential Australian innovations” and “homegrown inventions could transform the lives of not only Australian patients, but people right across the world”. Dr Jodie Marquez, one of the only Australian scientists to have studied the legs, was in attendance. “At that presentation Greg Hunt was saying ‘this is great Australian-owned technology’. But it never was,” she said. “This was always New Zealand’s. But now we’re claiming it as Australian, we’ve invested in it.” A spokesman for Mr Hunt said “neither the minister nor the government are the decision maker in relation to BTF program investments and their commercial terms”. He said the government had received advice from BioScience Managers the investment met the Biomedical Translation Fund’s guidelines. “A mechanism for dealing with conflicts of interest is included in the governing documents of each fund and is overseen by an advisory board,” a government spokeswoman said. “The department cannot provide specific details of individual conflicts of interest.” Rex Bionics was founded by a pair of engineers in an Auckland garage in 2007, before listing on a lower-tier British-based stock exchange in 2014. It has received millions of dollars from the New Zealand government in research and development grants. Rex Bionics chief technology officer Richard Little puts New Zealand Prime Minister John Key through his paces during a 2016 visit Credit:Rex Bionics / Supplied But Rex struggled to sell its exoskeletons, and in 2017 came close to insolvency. When Rex listed on the British stockmarket in 2014, listing documents noted its “success depends to a significant degree” on the technical skills of co-inventor Richard Little. He left the company in 2017, and told The Sunday Age he had really left much earlier than that. “They had their plans in place. They weren’t really my plans,” he said. “I really did step back from that sort of side of things. I was such a minority shareholder – it wasn’t really my company at that stage. I felt close to the product, but not the company.” Rex now says it is working with Melbourne-based engineering company Hydrix on redesigning and upgrading the exoskeleton. Asked how much of Rex’s operations were in Australia, Rex’s CEO Charles Carignan said the company was now based in Melbourne. However, it employed only a single person in Australia - although there were plans to increase that to three or four. “Unfortunately, the last 15 months of no travel, has been a challenge for the company. We actually had some people who left because of that, that now we’re fortunately bringing back.” In 2016, a charity part-funded a clinical trial of Rex’s exoskeleton in the Hunter Valley. That trial revealed a number of key flaws with the expensive exoskeleton, said lead investigator Dr Jodie Marquez from the University of Newcastle. For example, the exoskeleton only comes in right-handed models. “If you have a stroke that effects your right-hand side, you are instantly ineligible. That’s 50 per cent of the stroke population,” she said. The device also has height and weight requirements for users – further limiting who can use it. “It is only so adjustable. People were either to tall, too short, or too fat to fit into the device,” she said. “Because of those restrictions regarding eligibility, clinical application of it is going to be very limited, to a restricted few.” Rex says the exoskeleton can be piloted by a physiotherapist, rather than the user, meaning the right-handed controls are not always an issue. The exoskeleton can hold people up to 193cm, but is limited to 100 kilograms - in line with other competing exoskeletons. However, the company said that all Rex’s exoskeleton suits in Australia are now past their maintenance schedule. The company’s British-based technician has been unable to visit and service them. Because of that, they cannot be safely used. Science and health explained and analysed with a rigorous focus on the evidence. Examine is a free weekly newsletter by science reporter Liam Mannix. Sign up to The Age’s here and the Sydney Morning Herald’s here . Start your day informed Our Morning Edition newsletter is a curated guide to the most important and interesting stories, analysis and insights. Sign up to The Sydney Morning Herald’s newsletter here , The Age’s here , Brisbane Times’ here , and WAtoday’s here . Save

BioScience Managers Investments

17 Investments

BioScience Managers has made 17 investments. Their latest investment was in Pharmamark Nutrition as part of their Unattributed VC on August 8, 2019.

CBI Logo

BioScience Managers Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/9/2019

Unattributed VC

Pharmamark Nutrition

$3.74M

Yes

1

5/17/2018

Series A - II

Canary Medical

$16M

Yes

1

4/24/2018

Unattributed VC

ADC Biotechnology

$1.59M

Yes

7

8/1/2017

Corporate Minority - II

Subscribe to see more

Subscribe to see more

10

2/20/2015

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/9/2019

5/17/2018

4/24/2018

8/1/2017

2/20/2015

Round

Unattributed VC

Series A - II

Unattributed VC

Corporate Minority - II

Series B

Company

Pharmamark Nutrition

Canary Medical

ADC Biotechnology

Subscribe to see more

Subscribe to see more

Amount

$3.74M

$16M

$1.59M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

7

10

10

BioScience Managers Portfolio Exits

2 Portfolio Exits

BioScience Managers has 2 portfolio exits. Their latest portfolio exit was ADC Biotechnology on April 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/7/2021

Acquired

5

2/5/2015

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/7/2021

2/5/2015

Exit

Acquired

IPO

Companies

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Sources

5

10

BioScience Managers Fund History

3 Fund Histories

BioScience Managers has 3 funds, including BioScience Managers Ventures I Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/11/2016

BioScience Managers Ventures I Fund

$50M

1

11/30/2012

OPBM Asia Pacific Healthcare Fund II

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2008

The Australian Bioscience Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

10/11/2016

11/30/2012

12/31/2008

Fund

BioScience Managers Ventures I Fund

OPBM Asia Pacific Healthcare Fund II

The Australian Bioscience Fund I

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$50M

$99M

$99M

Sources

1

10

10

BioScience Managers Partners & Customers

1 Partners and customers

BioScience Managers has 1 strategic partners and customers. BioScience Managers recently partnered with Canary Medical on August 8, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

8/1/2017

Partner

Canada

Canary Medical and BioScience Managers form CHARM Informatics – BioScience Managers

BioScience Managers commits AUS$ 10M to new joint venture with Canary Medical to serve as a platform to collect and monetize data from implantable and wearable medical devices .

3

Date

8/1/2017

Type

Partner

Business Partner

Country

Canada

News Snippet

Canary Medical and BioScience Managers form CHARM Informatics – BioScience Managers

BioScience Managers commits AUS$ 10M to new joint venture with Canary Medical to serve as a platform to collect and monetize data from implantable and wearable medical devices .

Sources

3

BioScience Managers Team

3 Team Members

BioScience Managers has 3 team members, including current Managing Director, Jeremy Curnock Cook.

Name

Work History

Title

Status

Jonathan Hepple

Founder

Current

Jeremy Curnock Cook

Valigen, and International Biotechnology Trust

Managing Director

Current

Bruce McHarrie

Senior Partner

Current

Name

Jonathan Hepple

Jeremy Curnock Cook

Bruce McHarrie

Work History

Valigen, and International Biotechnology Trust

Title

Founder

Managing Director

Senior Partner

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.